This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-13. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== External links == Processing Radioactive Materials - large set of images by the IAEA showing automated package labelling and tracking for shipment of hazardous radioactive pharmaceuticals. FDA Compliance Policy Guides - CPG Sec. 450.500 Tamper-Resistant Packaging Requirements for Certain Over-the-Counter Human Drug Products
== Notable environmental chemists == Joan Berkowitz Paul Crutzen (Nobel Prize in Chemistry, 1995) Philip Gschwend Alice Hamilton John M. Hayes Charles David Keeling Ralph Keeling Mario Molina (Nobel Prize in Chemistry, 1995) James J. Morgan Clair Patterson Roger Revelle Sherry Roland (Nobel Prize in Chemistry, 1995) Robert Angus Smith Susan Solomon Werner Stumm Ellen Swallow Richards Hans Suess John Tyndall
===== Phase II ===== Bromazolam N-glucuronide, phenyl-hydroxy bromazolam glucuronide, α-hydroxy bromazolam glucuronide, and 4-hydroxy bromazolam glucuronide, were detected as phase II metabolites. Bromazolam N-glucuronidation was found to be catalysed by UGT1A4 and UGT2B10. The formation of α-hydroxy bromazolam glucuronide was catalysed by UGT2B4. And 4-hydroxy bromazolam glucuronidation was catalysed by UGT1A3, UGT1A6, UGT1A9, UGT2B7 and UGT2B15. The enzyme responsible for the catalysis for the phenyl-hydroxy bromazolam glucuronidation formation was not identified.
Robert Allan Humphreys (1930–1988), known as Laud Humphreys, was an American sociologist and Episcopal priest. He is noted for his research into sexual encounters between men in public bathrooms, published as Tearoom Trade (1970), and for the questions that emerged regarding the ethical nature of his research methods. He influenced generations of scholars who research issues related to sexuality and sexual identity.
On August 6, 1945, the uranium-type nuclear weapon codenamed "Little Boy" was detonated over the Japanese city of Hiroshima with an energy of about 15 kilotons of TNT (63,000 gigajoules), destroying nearly 50,000 buildings (including the headquarters of the 2nd General Army and Fifth Division) and killing approximately 70,000 people, including 20,000 Japanese combatants and 20,000 Korean slave laborers. Three days later, on August 9, a plutonium-type nuclear weapon codenamed "Fat Man" was used against the Japanese city of Nagasaki, with the explosion equivalent to about 20 kilotons of TNT (84,000 gigajoules), destroying 60% of the city and killing approximately 35,000 people, including 23,200–28,200 Japanese munitions workers, 2,000 Korean slave laborers, and 150 Japanese combatants. The industrial damage in Nagasaki was high, partly owing to the inadvertent targeting of the industrial zone, leaving 68–80 percent of the non-dock industrial production destroyed. The U.S., despite not having a third device ready to be dropped, gave Japan one last warning that there would be another bombing if they did not surrender, and the target would be Tokyo. Six days after the detonation over Nagasaki, Japan announced its surrender to the Allied Powers on August 15, 1945, signing the Instrument of Surrender on September 2, 1945, officially ending the Pacific War and, therefore, World War II, as Germany had already signed its Instrument of Surrender on May 8, 1945, ending the war in Europe.
Sources: en.wikipedia.org
While praising the quality of its offering, industry commentators attributed Arivale's closure to a failure to capture sufficient Customer lifetime value to create a profit from providing the service, suggesting that insufficient numbers of customers stuck with the data-driven, personalized dietary and lifestyle coaching it provided for long enough at a price point which would make the business model work.
=== From organic halides and cyanide salts === Two salt metathesis reactions are popular for laboratory scale reactions. In the Kolbe nitrile synthesis, alkyl halides undergo nucleophilic aliphatic substitution with alkali metal cyanides. Aryl nitriles are prepared in the Rosenmund-von Braun synthesis. In general, metal cyanides combine with alkyl halides to give a mixture of the nitrile and the isonitrile, although appropriate choice of counterion and temperature can minimize the latter. An alkyl sulfate obviates the problem entirely, particularly in nonaqueous conditions (the Pelouze synthesis). In the Kolbe nitrile synthesis (a nucleophilic substitution reaction), an alkanonitrile and an alkali halide are formed from a reactive halocarbons and an alkali cyanide (sodium cyanide or potassium cyanide). The reaction is particularly suitable for primary, allylic, and benzylic halides. Secondary alkyl halides provide lower yields, whereas tertiary halides undergo exclusively elimination reaction instead of substitution. In addition to halides, substrates bearing other good leaving groups may also be employed. In contrast to alkali cyanides, silver cyanide is unsuitable for nitrile synthesis, as it preferentially forms isonitriles. An example of the Kolbe nitrile synthesis is the reaction of methyl iodide with sodium cyanide to yield acetonitrile and sodium iodide:
The metabolism of drugs is mainly by metabolic enzyme cytochrome P450, and this enzyme is not active in skin. The CYP450 actively metabolized drugs can then maintain high concentration when being applied on skin. Despite CYP450 enzyme action, the partition coefficient (K) determines the activity of topical drugs. The ability of drug particles to go through the skin layer also affects the absorption of drugs. For transdermal activity, medicines with higher K value are harder to get rid of the lipid layer of skin cells. The trapped molecules then cannot penetrate into the skin. This reduces the efficacy of the transdermal drugs. The drugs target cells underneath the skin or need to diffuse into blood capillary to exert their effect. Meanwhile, the size of particles affects this transdermal process. The smaller the drug molecules, the faster the rate of penetration. Polarity of the drugs can affect this diffusion rate too. If the drug shows lower degree of ionization, it is less polar. Therefore, it can have a faster absorption rate.
This means that the cancer cells don't look like normal epithelial cells and instead look more abnormal under a microscope with poorly differentiated tumors being very dangerous. These types of tumors grow faster, are more invasive, metastasize more, and have a worse prognosis. The galectin-7 protein still can't prevent the cancer entirely but there is still an association between its reduced presence and links to a worsened tumor prognosis. In a study transfecting and comparing the human colon carcinoma cell with a galectin-7 expression, it was found that the protein cells are more sensitive to apoptotic stimuli and has a reduced proliferation in vitro. The strong suppression of tumor formation was discovered when injected subcutaneously into immunodeficient mice. Galectin-7 was found to have a tumor-suppressive effect in the colon carcinoma model, though this is just one context dependent example of galectin-7 being used for anti-tumorigenic purposes.
The documentation surrounding a spreadsheet containing a simple but "GxP" critical calculation should not match that of a Chromatography Data System with 20 Instruments) Determination of a "GxP critical" requirement for a computer system is subjective, and the definition needs to be tailored to the organisation involved. However, in general a "GxP" requirement may be considered to be a requirement which leads to the development/configuration of a computer function which has a direct impact on patient safety, the pharmaceutical product being processed, or has been developed/configured to meet a regulatory requirement. In addition if a function has a direct impact on GxP data (security or integrity) it may be considered "GxP critical".
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.